Lederle
Executive Summary
Countersues Mylan May 28 in Clarksburg, W.V. federal court in response to Mylan's November 1990 suit claiming that Lederle failed to adequately support Maxzide (triamterene/hydrochlorothiazide), resulting in "underpayment" to Mylan ("The Pink Sheet" Dec. 10, T&G-2). Lederle, which is seeking $ 607 mil. in compensatory damages and $ 75 mil. in punitive damages, denies all of Mylan's claims and makes counterclaims for: fraudulent inducement, alleging that Mylan misrepresented its patented process to preclude competition; breach of contract, by failing to satisfy the challenge of bioavailability; and defamation, by allegedly making false statements that parent American Cyanamid was not placing Maxzide orders with Mylan.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth